On December 10th, Southern Finance and Economics reported that Merck announced the use of its antifungal drug, NozoNobel&Co; reg; The new indications for two dosage forms, Bosaconazole enteric coated tablets and Bosaconazole injection, have been approved by the Drug Evaluation Center of the China National Medical Products Administration, expanding the prevention and treatment population to pediatric patients. Among them, Posaconazole enteric coated tablets are approved for the prevention of invasive aspergillosis and candidiasis caused by severe immunodeficiency in adults and children aged ≥ 2 years and weighing over 40kg, as well as for the treatment of invasive aspergillosis in patients aged ≥ 13 years; Posaconazole injection is approved for the prevention of invasive aspergillosis and candidiasis caused by severe immunodeficiency in adult and pediatric patients aged ≥ 2 years, as well as for the treatment of invasive aspergillosis in patients aged ≥ 13 years. (21st Century Business Herald)